116 related articles for article (PubMed ID: 8265124)
1. [Immunotherapy of superficial bladder tumors in a hospital department].
Prekopp G; Rosdy E
Orv Hetil; 1993 Dec; 134(50):2757-60. PubMed ID: 8265124
[TBL] [Abstract][Full Text] [Related]
2. [Results obtained by intravesical instillation of BCG in superficial bladder tumors].
Romics I; Dietmar B; Christoph R
Orv Hetil; 1990 Jan; 131(1):25-8. PubMed ID: 2405331
[TBL] [Abstract][Full Text] [Related]
3. [Adjuvant BCG immunotherapy in the management of superficial bladder tumors].
Somogyi L; Szántó A; Polyák L; Baranyay F; Drinóczy M
Orv Hetil; 1993 Aug; 134(34):1851-6. PubMed ID: 8355975
[TBL] [Abstract][Full Text] [Related]
4. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
[TBL] [Abstract][Full Text] [Related]
5. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
6. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
[TBL] [Abstract][Full Text] [Related]
7. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
8. [Microdoses of BCG vaccine for prophylaxis in bladder cancer stage T1].
Rivera P; Caffarena E; Cornejo H; Del Pino M; Fonerón A; Haemmersli J; Sepúlveda M; Ubilla A
Actas Urol Esp; 1993 Apr; 17(4):243-6. PubMed ID: 8342414
[TBL] [Abstract][Full Text] [Related]
9. [Repeated yearly BCG treatment in superficial bladder cancer].
Somogyi L; Török A; Bors G; Drinóczy M; Horváth R
Orv Hetil; 1989 Mar; 130(13):671-3. PubMed ID: 2726237
[TBL] [Abstract][Full Text] [Related]
10. [The intravesical administration of BCG vaccine in treating recurrent superficial bladder cancer].
Panteleeva ES; Neprina GS; Vatin OE; Kariakin OB; Safiullin KN
Urol Nefrol (Mosk); 1997; (2):29-32. PubMed ID: 9206879
[TBL] [Abstract][Full Text] [Related]
11. [Topical immunotherapy with BCG in the adjuvant treatment of superficial bladder tumors--15-year-experience].
Geavlete P; Georgescu D; Arabagiu I
Chirurgia (Bucur); 2000; 95(2):157-68. PubMed ID: 14768319
[TBL] [Abstract][Full Text] [Related]
12. [Prophylaxis of superficial bladder cancer with 1 mg of intravesical BCG: comparison with other doses].
Corti Ortíz D; Rivera Garay P; Avilés Jasse J; Hidalgo Carmona F; MacMillan Soto G; Coz Cañas LF; Vargas Delaunoy R; Susaeta Saénz de San Pedro R
Actas Urol Esp; 1993 Apr; 17(4):239-42. PubMed ID: 8342413
[TBL] [Abstract][Full Text] [Related]
13. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
14. [The immunotherapy of bladder tumors and the immunoprophylaxis of disease recurrence].
Korovin AI; Savvin VT
Urol Nefrol (Mosk); 1996; (1):19-21. PubMed ID: 8659034
[TBL] [Abstract][Full Text] [Related]
15. [BCG in superficial carcinoma of the bladder. Authors' experience].
Bordalba Gómez JR; Muñoz Segui J; Aguilo F; Gil Vernet A; Vigues F; Lopez Costea MA; Serrallach N
Actas Urol Esp; 1992 Jun; 16(6):443-5. PubMed ID: 1509911
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of stage Ta,T1 and Tis bladder tumors using Calmette-Guérin bacillus vaccine].
Bretheau D; Lechevallier E; Rossi D; Albert P; de Fromont M; Coulange C
Prog Urol; 1993; 3(4):608-17. PubMed ID: 8401621
[TBL] [Abstract][Full Text] [Related]
17. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
18. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
19. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
20. [Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
Ayed M; Ben Hassine L; Ben Slama R; Chelbi N; Ghozzi S; Drissi H; Jemni M; Chebil M
Prog Urol; 1998 Apr; 8(2):206-10. PubMed ID: 9615929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
